Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential?

Omeros Corporation (NASDAQ:OMER) is one of the hot stocks to buy with huge upside potential. On October 15, H.C. Wainwright raised the firm’s price target on Omeros to $20 from $9 and kept a Buy rating on the shares. This sentiment followed the company’s announcement of an asset purchase and license agreement with Novo Nordisk (NYSE:NVO) for zaltenibart.

Omeros is set to receive an upfront cash payment of $240 million, with the potential for an additional $510 million in one-time payments tied to development and approval milestones. Furthermore, the agreement includes up to $1.3 billion in one-time, sales-based milestone payments, along with tiered royalties on the products’ annual net sales.

Novo Nordisk (NYSE:NVO), together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products internationally. It has two segments: Diabetes & Obesity Care and Rare Disease.

Omeros Corporation (NASDAQ:OMER) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

While we acknowledge the potential of OMER as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.